Document:

Agreement for Purchase and Sale of Patent Rights and License Back Agreement

 Exhibit 10.1 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Asterisks denote omissions. 

AGREEMENT FOR PURCHASE AND SALE OF PATENT RIGHTS AND LICENSE BACK 

This Agreement (hereinafter referred to as the “Agreement”) is entered into as of the 23
rd day of June, 2010 (the “Effective Date”) by
and between Icagen, Inc., a Delaware corporation (“Icagen”) and Applied Genetic Technologies Corporation, a Delaware corporation (“AGTC”). 

RECITALS: 

A.    Icagen is the owner of the Patent Rights as set forth below. 

B.    AGTC desires to acquire from Icagen, and Icagen desires to sell, transfer, assign and convey to
AGTC, all right, title and interest in and to the Patent Rights upon the terms and conditions set forth in this Agreement. 

C.    AGTC has agreed to grant back to Icagen a license under the Patent Rights as set forth and upon
the terms and conditions in this Agreement. 
 NOW, THEREFORE, in consideration of the premises contained in
this Agreement and for good and valuable consideration, the receipt, adequacy and sufficiency of which are hereby acknowledged, the parties agree as follows: 

ARTICLE 1 – DEFINITIONS 

Except as otherwise defined in this Agreement, capitalized terms used herein shall have the following definitions:

 1.1    “Affiliate” shall mean any entity directly or indirectly controlled by,
controlling or under common control with a party. “Control shall mean with respect to an entity, possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such entity (whether through
ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable
equity interests 
 1.2    “Confidential Information” means all information
(whether or not patentable) regarding a party’s technology, products, business or objectives. Notwithstanding the foregoing, Confidential Information shall not include information that: (a) was known or used by the receiving party or its
Affiliates prior to its date of disclosure to the receiving party; or (b) either before or after the date of the disclosure to the receiving party is lawfully disclosed to the receiving party or its Affiliates by sources other than the
disclosing party rightfully in possession of such information and not bound by confidentiality obligations to the disclosing party; or (c) either before or after the date of the disclosure to the receiving party or its Affiliates is or becomes
published or otherwise is or becomes part of the public domain through no breach hereof on the part of the receiving party or its Affiliates; or (d) is independently developed by or for the receiving party or its Affiliates without reference to
or reliance upon the Confidential Information of the disclosing party as demonstrated by written records contemporaneously maintained. 

1.3    “Dominating Patent” shall mean a patent which has a claim broad enough to
encompass the subject matter of an invention claimed in a subsequent patent, such that (a) the patentee of the Dominating Patent is able to prevent the patentee of the subsequent patent from practicing his/her/its

 
“improvement” invention and (b) the patentee of the subsequent patent is able to prevent the patentee of the Dominating Patent from practicing the “improved” invention
only, but not the original invention. 
 1.4    “Encumbrance” means any
lien, claim, charge, security interest, mortgage, pledge, easement, conditional sale or other title retention agreement, defect in title, covenant or other restrictions of any kind. 

1.5    “Icagen Field” means the field of small molecule human therapeutics.

 1.6    “Improvements” means any enhancement, modification, development,
alteration or other improvement to the Patent Rights made by or on behalf of Icagen, provided, that one or more of the Patent Rights listed in Exhibit A as of the Effective Date is a Dominating Patent with respect to such improvement.

 1.7    “Patent Rights” means the patents and patent applications listed
in Exhibit A and all reissues, reexaminations, divisionals, continuations, continuations-in-part, extensions, foreign counterpart or other patents claiming priority thereto. 

ARTICLE 2 – PURCHASE AND SALE 

2.1    Purchase and Sale. On the terms and subject to the conditions of this Agreement, Icagen
hereby sells, conveys, assigns and transfers to AGTC, and AGTC purchases from Icagen, all right, title and interest of Icagen in and to the Patent Rights free and clear of all Encumbrances. Simultaneously with the execution of this Agreement, Icagen
shall deliver to AGTC an assignment of the Patent Rights in substantially the form attached hereto as Exhibit C (the “Assignment”). Upon delivery of the Purchase Price, AGTC shall have the right to record the Assignment with
the U.S. Patent and Trademark Office and each other patent office of relevant jurisdiction, such recordation to be at AGTC’s sole expense. Notwithstanding the delivery of the Assignment, Icagen agrees to perform or cause to be done and
performed all such further acts and furnish, execute and deliver such other documents, instruments, certificates, notices or other further assurances as AGTC reasonably requests, from time to time after the Effective Date, to effect, evidence or
perfect the Assignment of the Patents Rights to AGTC, free and clear of any Encumbrance. 

2.2.    Information. Promptly following the Effective Date, Icagen shall, or shall instruct
its outside patent counsel to, provide to AGTC or its designated counsel a list of prosecution counsel, the docket, and all files and original documents (including Letters Patent and assignments) relating to the Patent Rights, including all
prosecution files for pending patent applications included in the Patents Rights. 

2.3    Purchase Price. In partial consideration of and for the sale, conveyance, transfer and
assignment by Icagen to AGTC of all right, title and interest in and to the Patent Rights, and subject to the execution and delivery of the Assignment, AGTC shall pay to Icagen the sum of U.S. One Million dollars ($1,000,000) (the “Purchase
Price”). 
 2.4    Method of Payment. The Purchase Price shall be paid to Icagen
within five (5) business days of the Effective Date by wire transfer of immediately available funds to the following account: [**], Credit to: Icagen, Inc. 
  

 Page 2 of 12 

 ARTICLE 3 – LICENSE BACK TO ICAGEN 

3.1    License Back to Icagen under Patent Rights. Effective on the Effective Date and
contingent upon the Assignment, AGTC hereby grants to Icagen, under the Patent Rights, and for the lives thereof, an exclusive (even as to AGTC), perpetual, irrevocable, royalty-free, sublicensable right and license for the purpose of research,
development, manufacture and commercialization of compounds and products in the Icagen Field. All rights and licenses granted under this Section 3.1 or pursuant to any section of this Agreement are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the United States bankruptcy code, licenses of rights to “intellectual property” as defined under Section 101(35A) of such statute. Icagen shall retain and may fully exercise all of its rights and
elections under the bankruptcy code. 
 3.2    Icagen Inventions. In the event that
at any time during the [**] year period commencing on the Effective Date, Icagen discovers, creates, conceives or reduces to practice any invention comprising an Improvement in the exercise of the license granted pursuant to Section 3.1 above
(“Covered Improvement”), each such Covered Improvement shall be AGTC’s sole property and Icagen agrees to assign, and hereby does assign to AGTC all right, title and interest in and to such Covered Improvement. Icagen further agrees
to take all such actions and execute all such assignment and other documents as may be necessary or desirable to effect or evidence such assignment and shall reasonably assist AGTC in filing for and/or prosecuting any patent applications for such
Covered Improvements. Upon such assignment, the Covered Improvement shall be deemed part of the Patent Rights for the purposes of this Agreement, including without limitation, for the purposes of the license grant pursuant to Section 3.1. To
the extent that Icagen discovers, creates, conceives or reduces to practice any invention comprising an Improvement subsequent to the [**] year period commencing upon the Effective Date, Icagen shall retain sole ownership of such Improvement,
including all intellectual property rights therein (“Icagen Improvements”), provided, however, that Icagen (including any successor-in-interest to the license granted pursuant to Section 3.1 above) shall not, directly or indirectly,
institute, maintain or prosecute, or voluntarily aid any third party in instituting, maintaining or prosecuting, any legal or equitable action or proceeding against AGTC or any sublicensee of the Patent Rights from AGTC based on infringement
resulting from its use or practice of any Icagen Improvements outside of the Icagen Field. 
 ARTICLE 4 –
REPRESENTATIONS AND WARRANTIES 
 4.1    Icagen Warranties. Icagen
hereby represents and warrants to AGTC as of the Effective Date that (i) it has all necessary corporate power and authority to enter into this Agreement and to assign the Patent Rights to AGTC, (ii) it is the exclusive owner of the Patent
Rights, (iii) the Patent Rights includes all patents and patents applications owned in part or in whole by Icagen claiming inventions specifically relating to the expression of the CNGB3 gene, and (iv) it has not received any charge,
complaint, claim, demand, or notice alleging that any use of inventions claimed in the Patent Rights constitutes infringement, misappropriation or violation of the intellectual property rights of any third party. 

4.2    AGTC’s Warranties. AGTC represents and warrants to Icagen that it has all
necessary corporate power and authority to enter into this Agreement and to undertake its obligations hereunder. 

4.3    Disclaimer of Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY, AND 
  

 Page 3 of 12 

 
EACH PARTY HEREBY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. 

ARTICLE 5 – PATENT PROSECUTION 

5.1    Preparation and Prosecution. Commencing upon the Effective Date, AGTC shall assume
control of all patent prosecution and maintenance of the Patent Rights, provided, however, AGTC will keep Icagen reasonably advised as to the prosecution status of all Patent Rights by directing patent counsel to forward to Icagen copies of all
official communications from or to the PTO or other governmental or patent office regarding the Patent Rights. Icagen shall have the right to review all official correspondence and filings made by or on behalf of AGTC with respect to such Patent
Rights, including without limitation, Office Action responses, prior to submission and AGTC agrees to reasonably consider Icagen’s timely input with respect thereto. All information regarding the filing, prosecution and maintenance of the
Patent Rights disclosed by AGTC to Icagen shall constitute AGTC’s Confidential Information, and shall not be used by Icagen other than for the research, development, manufacture and commercialization of compounds or products in accordance with
the license granted to Icagen in Section 3.1 or as otherwise permitted pursuant to Article 8. 

5.2    In the event that AGTC does not wish to continue to prosecute or maintain any patent
applications, claims included in the patent applications or patents within the Patent Rights, then AGTC shall notify Icagen sufficiently prior to abandoning any such patent applications, claims or patents to enable Icagen to assume responsibility
and control of the prosecution and maintenance of such applications, claims or patents without any loss of rights, and Icagen shall have the right to assume responsibility and control of the prosecution and maintenance of such applications, claims
or patents in AGTC’s name and at Icagen’s sole expense. 
 5.3    Prior Patent
Costs. Notwithstanding anything herein to the contrary, Icagen shall be solely responsible for all costs and expenses associated with the filing, prosecution or maintenance of the Patent Rights accrued prior to the Effective Date (it being
understood that fees first due to patent offices (excluding any applicable grace period) that do not become due until after the Effective Date shall be deemed not to have accrued until after the Effective Date). Attached hereto as Exhibit
B is a current docket showing all prosecution, registration or maintenance actions and fees that shall become due within sixty (60) days following the Effective Date. 

ARTICLE 6 – INFRINGEMENT 

6.1     Each party agrees to promptly provide written notice to the other party if such party becomes
aware of any infringement of Patent Rights. 
 6.2    AGTC shall have the sole and exclusive
right to undertake the enforcement and/or defense of the Patent Rights outside of the Icagen Field in its sole discretion and at its sole expense. Any recovery by AGTC in any such action shall belong solely to AGTC 

6.3    Icagen shall have the primary right, at its sole expense, to undertake the enforcement of the
Patent Rights against any infringement of the Patent Rights in the Icagen Field, including without limitation, the right to settle the infringement or misappropriation suit by sublicensing the Patent Rights the alleged infringer (but only in
accordance with the provisions of this Agreement) or by other means reasonably acceptable to Icagen. If Icagen undertakes enforcement of the Patent Rights in the Icagen Field, any recovery by Icagen in such action shall belong solely to Icagen.

  

 Page 4 of 12 

 6.4    If Icagen does not settle such activity (whether
by granting a sublicense in the Icagen Field or otherwise) or institute legal action against the infringing activity in the Icagen Field within three (3) months of having been given notice of the infringing activity and that one or more of the
following conditions relating to such infringing activity exists: (a) there is an infringing commercial product on the market; (b) an infringing commercial product is not yet on the market but an application for regulatory approval for an
infringing commercial product has been accepted for filing by the applicable regulatory authority; or (c) the failure to enforce the Patent Rights with respect to such infringing activity could reasonably be expected to adversely affect the
scope or validity of the Patent Rights or AGTC’s legal ability to enforce the Patent Rights outside the Icagen Field, then AGTC shall have the right, but shall not be obligated, to prosecute at its own expense any such infringements of the
Patent Rights in the Icagen Field. Any recovery by AGTC shall belong solely to AGTC. 

6.5    In any infringement suit instituted by either party to enforce the Patent Rights, the other
party shall, at the request and expense of the party initiating such suit, cooperate in all reasonable respects (including by agreeing to be joined as a party to such suit if necessary or desirable to bring or maintain such suit or to establish
damages in such suit) and, to the extent reasonably possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like. 

ARTICLE 7 – INDEMNIFICATION 

7.1    Indemnification by Icagen. Icagen agrees to indemnify, defend and hold harmless AGTC,
and its Affiliates and their directors, officers, employees and agents (individually and collectively, the “AGTC Indemnitees”) harmless from and against any and all losses, liabilities, damages and expenses (including reasonable
attorneys’ fees and costs) incurred in connection with any claims, demands, actions or other proceedings by any third party (individually and collectively, “Liability”) arising out of or relating in any way to (a) the
exercise of the Patent Rights by Icagen prior to the Effective Date or the exercise of the Patent Rights by Icagen pursuant to the licenses granted herein in the Icagen Field or (b) any breach of any representation, warranty, covenant or
agreement under this Agreement by Icagen or its Affiliates. 
 7.2    Indemnification by
AGTC. AGTC agrees to indemnify, defend and hold harmless Icagen and its Affiliates and their, directors, officers, employees and agents (collectively, “Icagen Indemnitees”), from and against any Liability arising out of or
relating in any way to (a) AGTC’s exercise of the Patent Rights other than arising out of intellectual property infringement of which Icagen was aware upon the Effective Date or out of Icagen’s exercise of the license granted pursuant
to Section 3.1 or (b) any breach of any representation, warranty, covenant or agreement under this Agreement by AGTC or its Affliates. 

7.3    Notice; Control. If any such claims or actions are made, the indemnified party shall:
(i) notify the indemnifying party promptly of such claim or action; and (ii) reasonably cooperate with the indemnifying party in the defense and/or settlement of such claim or action. The indemnifying party shall have the right to control
the defense of any such claim or action, at its sole expense, using counsel selected by the indemnifying party and reasonably acceptable to the indemnified party. The indemnified party may, at its own expense, also be represented by counsel of its
own choosing. 
 7.4    Limitation. A party’s indemnification obligations under
this Section 7 shall not apply to any Liability which, as determined by final judgment, would not have arisen in the absence of the negligence and/or intentional misconduct of any of the indemnified parties. 

 

 Page 5 of 12 

 7.4    Settlement. The indemnifying party may
settle any such claim, demand, action or other proceeding or otherwise consent to an adverse judgment (a) with prior written notice to the indemnified party but without the consent of the indemnified party where the only liability to the
indemnified party is the payment of money and the indemnifying party (or its insurer) makes such payment, or (b) otherwise only with the prior written consent of the indemnified party, which consent shall not be unreasonably withheld.

 ARTICLE 8 – CONFIDENTIALITY 

8.1.    Confidential Information. Each party agrees that all Confidential Information
disclosed to it by the other party (a) shall not be used by the receiving party except in connection with the activities contemplated by this Agreement or in order to further the purposes of this Agreement, (b) shall be maintained in
confidence by the receiving party, and (c) shall not be disclosed by the receiving party to any third party who is not an affiliate or consultant of, or an advisor to, or a stockholder of, or lender to, or a prospective investor in or
prospective lender to, or a sublicensee or prospective sublicensee, collaborator, prospective collaborator, or potential merger partner or acquirer of the receiving party without the prior written consent of the disclosing party. 

8.2.    Disclosures to Employees, Consultants and Advisors. Each party agrees that it shall
provide Confidential Information received from the other party only to the receiving party’s respective employees, consultants and advisors, and to the employees, consultants and advisors of the receiving party’s affiliates, who have a
need to know such Confidential Information to assist the receiving party in fulfilling its obligations under this Agreement, provided that the parties shall each remain responsible for any failure by its and its affiliates’ respective
employees, consultants and advisors to treat such information and materials as required under Section 8.1. 

8.3.     Legally Required Disclosures. If Confidential Information of the disclosing party is
required to be disclosed by the receiving party to comply with applicable laws or regulations, including without limitation disclosure rules under applicable securities laws or stock exchange regulations, then the receiving party shall be permitted
to make the required disclosure; provided that the receiving party provides, if legally permissible and practicable under the circumstances, prior written notice of such disclosure requirement to the disclosing party and, if requested by the
disclosing party, cooperates with the disclosing party’s reasonable and lawful actions to avoid and/or minimize the degree of such required disclosure, including without limitation by cooperating with the disclosing party’s efforts to
obtain confidential treatment (to the extent available) from the applicable governmental or regulatory body. 

8.4.     Confidentiality Term. All obligations of confidentiality imposed under this
Section 8 shall expire upon the fifth (5th) anniversary of the expiration or termination of this Agreement. 

ARTICLE 9 – MISCELLANEOUS PROVISIONS 

9.1    No Waiver. The respective representations and warranties of each party hereto contained
herein shall not be deemed waived or otherwise affected by any investigation made by the other party hereto. 
  

 Page 6 of 12 

 9.2    Notices and other communications. Any
notice or other communication required by this Agreement or by applicable law shall be made or given in writing and (i) delivered in person, (ii) sent by registered or certified mail, postage prepaid, or (iii) sent by overnight
courier such as Federal Express or DHL, and addressed as set forth below: 
  

			
	 To AGTC:
	  	 Applied Genetic Technologies Corporation

Attn: Susan B. Washer, President & CEO

11801 Research Drive
 Suite D,
Alachua, Florida 32615
 Fax: (386 ) 462-7396

		
	 To Icagen:
	  	 Icagen, Inc.
 Attn:
President
 4222 Emperor Boulevard

Suite 350
 Durham, NC 27703

Fax: (919) 941-0813

or to such other address as such party may indicate by a notice delivered to the other party hereto. Notices will be deemed to have been
given at the time of actual delivery in person, three (3) business days after deposit in the mail as set forth herein, or one (1) business day after delivery to an overnight courier service 

9.3    Assignment; Successors and Assigns. This Agreement may not be assigned by either party
without the prior written consent of the other party; provided, however, that either party may assign this Agreement and the rights and licenses granted hereunder without the consent of the other party (but with notice) to any Affiliate of the
assigning party or to a successor entity in connection with the sale or other transfer of the assigning party’s business relating to the Patent Rights or of all or substantially all of the stock or assets of the assigning party, whether by
merger, acquisition or otherwise. Each party shall give the other party prompt written notice of an assignment or transfer of this Agreement. 

9.4    Access to Records after Closing Date. For a period of five (5) years after the
execution of this Agreement, AGTC and its representatives shall have reasonable access to all of the information, books and records of Icagen related to the Patent Rights, including without limitation, invention logs and notebooks, which Icagen may
retain after the execution of this Agreement for the purpose of prosecution, maintenance or enforcement of the Patent Rights. Such access shall be afforded by Icagen upon receipt of reasonable advance notice and during normal business hours and in a
manner that does not significantly impair or impede the business operations of Icagen. 

9.5    Entire Agreement; Amendments. This Agreement, including all attachments, all of which
this Agreement incorporates by reference, sets forth the entire agreement and understanding between the parties and supersedes and cancels all previous negotiations, agreements and commitments, whether oral or in writing, with respect to the subject
matter described herein, and neither party shall be bound by any term, clause, provision, or condition, save as expressly provided in this Agreement or as duly set forth in writing as a subsequent amendment to this Agreement, signed by duly
authorized officers of each party. This Agreement shall not be amended, modified or supplemented, except by a written amendment signed by an authorized representative of each of the parties hereto. 

 

 Page 7 of 12 

 9.6    No Consequential or Punitive Damages.
NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, PUNITIVE OR MULTIPLE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, OR FOR ANY LOSS OR INJURY TO A PARTY’S PROFITS
OR GOODWILL ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 9.6 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY WITH RESPECT TO
THIRD PARTY CLAIMS. 
 9.7    Governing Law. This Agreement shall be governed by and
construed in accordance with the State of New York, excluding any of its conflicts of law principles that would dictate the application of the substantive law of any other jurisdiction. 

9.8    No Partnership, Joint Venture or Agency. Nothing contained in this Agreement will be
deemed to place the parties in a partnership, joint venture or agency relationship, and neither party will have the right or authority to obligate or bind the other party in any manner. 

9.9    Counterparts. This Agreement may be executed in two or more counterparts, each of which
will be deemed an original and all of which together constitute one instrument. 
 [Signatures on following page.] 

 

 Page 8 of 12 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above. 
 APPLIED GENETIC TECHNOLOGIES CORPORATION 

 

			
	 By:   
	 	 /s/ Susan B. Washer

		 	 Susan B. Washer

		 	 President and CEO

	
	 ICAGEN, INC.

		
	 By:   
	 	 /s/ P. Kay Wagoner

		 	 P. Kay Wagoner

		 	 President and CEO

  

 Page 9 of 12 

 EXHIBIT A 

PATENT RIGHTS 
  

															
	
TTC Ref
No.

Attys 
Handling    
	  	Client’s Ref No    
	  	Title                    
	  	Inventor                
	  	
App No.

Filing Date        

	  	
Pat No.

Issue 
Date        
	  	
Pub No.

Pub 
Date        
	  	Status
 & Remarks
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	 	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]

 EXHIBIT “B” 

2-MONTH DOCKET 

[**] 

 EXHIBIT “C” 

PATENT ASSIGNMENT 

WHEREAS, Icagen, Inc., a Delaware corporation having a mailing address of 4222 Emperor Boulevard, Suite 350,
Durham, NC 27703 (hereinafter referred to as “Assignor”), owns the entire right, title and interest in and to the following patents and patent applications: 
  

					
	 PATENT
	 	DATE OF ISSUANCE	 	INVENTOR(S)
		 		 	
		 		 	
			
	 PATENT APPLICATION
	 	DATE OF FILING	 	
		 		 	
		 		 	

 WHEREAS, Applied Genetic Technologies, Inc., a Delaware corporation having
a mailing address of 11801 Research Drive, Suite D, Alachua, FL 32615 (hereinafter referred to as “Assignee”) is desirous of acquiring the entire right, title, and interest in and to the aforesaid patents and patent applications, and to
all related intellectual property; and 
 WHEREAS, Assignor and Assignee are desirous of confirming the
assignment for purposes of filing the same with the United States Patent and Trademark Office and other appropriate governmental offices. 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor hereby
sells, transfers, assigns and delivers unto Assignee, effective as of the date hereof, the entire right, right, title and interest in and to the aforesaid patents and patent applications, and to all reissues and reexaminations thereof, as well as
the underlying invention(s) and all improvements thereto, and all continuations, continuations-in-part, and further or other proceedings of any kind whatsoever embodied in, related to or associated with the aforesaid patents and patent applications.
Assignor hereby agrees to cooperate with Assignee hereunder in all such legal actions by Assignee but at Assignee’s expense. 

IN WITNESS WHEREOF, this Assignment has been executed by on behalf of Assignor by its duly authorized officer as
of the date hereof. 
 Icagen, Inc. 
  

			
	 By:
	 	
		 	 
		 	 P. Kay Wagoner, President and CEO

		 	
	
	  

	 Date
	 	

 PATENT ASSIGNMENT 

WHEREAS, Icagen, Inc., a Delaware corporation having a mailing address of 4222 Emperor Boulevard, Suite 350,
Durham, NC 27703 (hereinafter referred to as “Assignor”), owns the entire right, title and interest in and to those patents and patent applications as set forth on Schedule A attached hereto: 

WHEREAS, Applied Genetic Technologies Corporation., a Delaware corporation having a mailing address of 11801
Research Drive, Suite D, Alachua, FL 32615 (hereinafter referred to as “Assignee”) is desirous of acquiring the entire right, title, and interest in and to the aforesaid patents and patent applications, and to all related intellectual
property; and 
 WHEREAS, Assignor and Assignee are desirous of confirming the assignment for purposes of
filing the same with the United States Patent and Trademark Office and other appropriate governmental offices. 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Assignor hereby
sells, transfers, assigns and delivers unto Assignee, effective as of the date hereof, the entire right, right, title and interest in and to the aforesaid patents and patent applications, and to all reissues and reexaminations thereof, as well as
the underlying invention(s) and all improvements thereto, and all continuations, continuations-in-part, and further or other proceedings of any kind whatsoever embodied in, related to or associated with the aforesaid patents and patent applications.
Assignor hereby agrees to cooperate with Assignee hereunder in all such legal actions by Assignee but at Assignee’s expense. 

IN WITNESS WHEREOF, this Assignment has been executed by on behalf of Assignor by its duly authorized officer as
of the date hereof. 
 Icagen, Inc. 
  

			
	 By:
	 	 /s/ P. Kay Wagoner

		 	 
		 	 P. Kay Wagoner, President and CEO

		 	
		 	June 23, 2010
	 
	 Date
	 	

 Schedule A 

 

											
	    Title     
           	  	Inventor            	  	 App.No

Filing Date            
	  	 Patent No.

Issue Date            
	  	 Publication No.

Publication Date            
	  	Status
	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

	     [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]Seller Subordinated Note

 Exhibit 4.8 

AFFINIA GROUP HOLDINGS INC. 

SELLER SUBORDINATED NOTE 
  

			
	U.S.$74,500,000	 	November 30, 2004

 FOR VALUE RECEIVED, the
undersigned, AFFINIA GROUP HOLDINGS INC. (the “Company”), a Delaware corporation, hereby unconditionally promises to pay to the order of DANA CORPORATION, a Virginia corporation, or its assigns (including any assignee or transferee
of, or other permitted holder of, this Note, the “Holder”) in lawful money of the United States of America on November 30, 2019 (the “Maturity Date’”) the principal sum of (a) SEVENTY-FOUR MILLION
FIVE HUNDRED THOUSAND DOLLARS, plus (b) the PIK Interest Portion (as defined herein) added to the principal amount of this Note pursuant to Section 2. This Note is referred to in, and was executed and delivered in connection with, that
certain Stock and Asset Purchase Agreement dated as of July 8, 2004, as amended on November 1, 2004, by and between Dana Corporation and Affinia Group Inc. (f/k/a AAG Opco Corp.) (“Affinia”), a Delaware corporation.

 SECTION 1. Definitions. 

The following terms shall have the respective meanings given to them in this Section 1. 

“Actual Prepayment Value” means, as of any date (the “Specified Date”), the amount provided below for
each U.S.$1,000 portion of the principal amount of the Note outstanding on the original date of issuance of this Note, plus the PIK Interest Portion of such portion of the Note: 

(1) if the Specified Date occurs on one of the following Interest Payment Dates, the Actual Prepayment Value will equal the amount set
forth below for such Interest Payment Date: 
  

				
	 November 30, 2005
	  	U.S.$	755.03
	 November 30, 2006
	  	 	849.41
	 November 30, 2007
	  	 	955.59
	 November 30, 2008
	  	 	1,075.04
	 November 30, 2009
	  	 	1,209.42
	 November 30, 2010
	  	 	1,360.59
	 November 30, 2011
	  	 	1,530.67
	 November 30, 2012
	  	 	1,722.00
	 November 30, 2013
	  	 	1,937.25

			
	 November 30, 2014
	  	2,179.41
	 November 30, 2015
	  	2,451.84
	 November 30, 2016
	  	2,758.32
	 November 30, 2017
	  	3,103.11
	 November 30, 2018
	  	3,490.99
	 November 30, 2019
	  	3,927.37

 (2) if the
Specified Date occurs before the first Interest Payment Date, the Actual Prepayment Value will equal the sum of (A) U.S.$671.14 and (B) an amount equal to the product of (x) the Actual Prepayment Value for the first Interest Payment
Date less U.S.$671.14 multiplied by (y) a fraction, the numerator of which is the number of days from November 30, 2004 to the Specified Date, and the denominator of which is 365; or 

(3) if the Specified Date occurs between two Interest Payment Dates, the Actual Prepayment Value will equal the sum of (A) the Actual
Prepayment Value for the Interest Payment Date immediately preceding such Specified Date and (B) an amount equal to the product of (x) the Actual Prepayment Value for the immediately following Interest Payment Date less the Actual
Prepayment Value for the Interest Payment Date immediately preceding such Specified Date multiplied by (y) a fraction, the numerator of which is the number of days from the immediately preceding Interest Payment Date to the Specified Date, and
the denominator of which is the actual number of days from the Interest Payment Date immediately preceding such Specified Date to the Interest Payment Date immediately following such Specified Date. 

“Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common
control with such Person. For purposes of this definition, “control” means the possession of the power to direct or cause the direction of management or policies of Person, whether through the ownership of voting securities, by contract or
otherwise. 
 “Affinia” is defined in the first paragraph of this Note. 

“Asset Sale Event” means any asset sale by the Company or any of its direct or indirect subsidiaries outside the ordinary course of
business, other than a sale relating to Affinia’s Beck/Arnley foreign nameplate distribution business or Quinton Hazell European parts supply business. 

“Bankruptcy Code” means the Bankruptcy Reform Act of 1978, as codified under Title 11 of the United States Code, and the rules
promulgated thereunder, as the same may be in effect from time to time. 

 “Business Day” means any day other than a Saturday, a Sunday or a day on which banks in New
York, New York are authorized or obligated by law to close. 
 “Change of Control” means a “Change of Control”
under and as defined in the Senior Subordinated Note Indenture. 
 “Change of Control Offer” is defined in paragraph
(b) of Section 3.3 of this Note. 
 “Change of Control Purchase Price” is defined in paragraph (a) of
Section 3.3 of this Note. 
 “Company” is defined in the first paragraph of this Note. 

“Credit Agreement” means that certain Credit Agreement, dated as of November 30, 2004, among Intermediate Holdings, Affinia, the
lenders from time to time party thereto, JPMorgan Chase Bank, as administrative agent, Goldman Sachs Credit Partners, L.P. and Credit Suisse First Boston, as co-syndication agents, and Deutsche Bank AG, Cayman Islands Branch, as documentation agent,
together with any Guaranties thereof by the Company or any of its subsidiaries, in each case, as amended, restated, supplemented, waived, replaced (whether or not upon termination and whether with the original lenders or otherwise), restructured,
refinanced, increased or otherwise modified from time to time. 
 “Designated Senior Debt” means all payment obligations of
Intermediate Holdings under its guaranty of its subsidiaries’ obligations under the Credit Agreement, the Senior Subordinated Note Indenture and any Receivables Financing. 

“Default” means an event or condition the occurrence or existence of which would, with the lapse of time or the giving of notice or
both, become an Event of Default. 
 “Dividend” means either (i) any dividend or other distribution in respect of, or any
redemption or repurchase of, the capital stock of the Company whether in cash, property or obligations of the Company, other than a dividend or other distribution payable solely in the form of its capital stock or (ii)(x) any dividend or other
distribution payable to any Investor or its subsidiaries in respect of, or (y) any redemption or repurchase from any Investor or its subsidiaries of, in either case, the capital stock of any subsidiary of the Company whether in cash, property
or obligations of such subsidiary, other than a dividend or other distribution payable solely in the form of its capital stock (provided that, for the purposes of this clause (ii), neither the Company nor a subsidiary of the Company shall be
considered a “subsidiary” of any Investor). 
 “Dividend Event” means the determination by (i) the Company to
pay any Dividend with the proceeds of a Recapitalization Event or an Asset Sale Event or (ii) any subsidiary of the Company to pay any Dividend to any Investor or its subsidiaries with 

 the proceeds of a Recapitalization Event or an Asset Sale Event (provided that, for the purposes of this
clause (ii), neither the Company nor a subsidiary of the Company shall be considered a “subsidiary” of any Investor). 

“Event of Default” is defined in Section 5. 

“Governmental Authority” means (a) the government of the United States of America or any State or other political subdivision
thereof, or any jurisdiction in which the Company conducts all or any part of its business, or which asserts jurisdiction over any properties of the Company, or (b) any entity exercising executive, legislative, judicial, regulatory or
administrative functions of, or pertaining to, any such government. 
 “Guaranty” means, with respect to any Person, any
obligation (except the endorsement in the ordinary course of business of negotiable instruments for deposit or collection) of such Person guaranteeing or in effect guaranteeing any Indebtedness, dividend or other obligation of any other Person in
any manner, whether directly or indirectly, including, without limitation, obligations incurred through an agreement, contingent or otherwise, by such Person: 

(a) to purchase such Indebtedness or obligation or any property constituting security therefor; 

(b) to advance or supply funds (1) for the purchase or payment of such Indebtedness or obligation, or (2) to
maintain any working capital or other balance sheet condition or any income statement condition of any other Person or otherwise to advance or make available funds for the purchase or payment of such Indebtedness or obligation; 

(c) to lease properties or to purchase properties or services primarily for the purpose of assuring the owner of such
Indebtedness or obligation of the ability of any other Person to make payment of the Indebtedness or obligation; or 

(d) otherwise to assure the owner of such Indebtedness or obligation against loss in respect thereof. 

In any computation of the Indebtedness or other liabilities of the obligor under any Guaranty, the Indebtedness or other obligations that are the subject
of such Guaranty shall be assumed to be direct obligations of such obligor. 
 “Intermediate Holdings” means Affinia Group
Intermediate Holdings Inc., a Delaware corporation, which is a guarantor under the Credit Agreement and the Senior Subordinated Notes Indenture. 

 “Indebtedness” with respect to any Person means, at any time, without duplication,

 (a) its liabilities for borrowed money; 

(b) all its liabilities in respect of letters of credit or instruments serving a similar function issued or accepted for
its account by banks and other financial institutions (whether or not representing obligations for borrowed money); 

(c) all obligations of such Person under any swap, cap, collar or similar arrangement providing for protection against
fluctuations in interest rates, currency exchange rates or commodities prices; and 
 (d) any Guaranty of such
Person with respect to liabilities of a type described in any of clauses (a) through (c) hereof. 
 “Insolvency
Proceeding” means (a) any case, action, or proceeding before any court or other Governmental Authority having jurisdiction over the applicable Person or its assets relating to bankruptcy, reorganization, insolvency, liquidation,
receivership, dissolution, winding-up, or relief of debtors or (b) any general assignment for the benefit of creditors, composition, marshaling of assets for creditors, or other similar arrangement in respect of its creditors generally or any
substantial portion of its creditors; in each case whether undertaken under Federal (including the Bankruptcy Code), state, or foreign law. 

“Interest Payment Date” means November 30 of each year, beginning November 30, 2005. 

“Interest Rate” means a rate of interest equal to 8.00% per annum, provided that after the fifth Interest Payment Date, the
rate of interest shall increase to 10.00% per annum. 
 “Investors” means (i) Cypress Merchant Banking
Partners II L.P. and Cypress Merchant Banking II C.V. (the “Initial Investors”) and (ii) any Person to whom the Initial Investors (or any subsequent transferee) transfers direct or indirect beneficial ownership of any the
capital stock of the Company. 
 “Management Stockholder” means, collectively, (i) any current or former employee or
consultant of the Company or its subsidiaries, (ii) the parents, spouses, former spouses, lineal descendants, heirs, executors, administrators, testamentary trustees, legatees or beneficiaries of the Persons described in clause (i),
(iii) for estate planning purposes, any trust, the beneficiaries of which include principally the Persons described in clauses (i) and (ii), and (iv) a corporation or partnership, a majority of the equity of which is owned and
controlled by principally the Persons described in clauses (i) and (ii). 

 “Maturity Date” is defined in the first paragraph of this Note. 

“Optional Prepayment Event” means any of the following events: 

(a) any Recapitalization Event; 

(b) any asset sale by the Company or any of its subsidiaries outside the ordinary course of business for an aggregate
purchase price (including assumed liabilities) in excess of U.S.$10,000,000; 
 (c) any asset sale relating to
substantially all of Affinia’s Quinton Hazell European parts supply business; or 
 (d) any offer and sale
of common stock or other equity securities of the Company or any of its subsidiaries pursuant to an effective registration statement under the Securities Act. 

“Parent” means any Person (other than an Investor or a Management Stockholder) who, directly or indirectly, beneficially owns any
capital stock of the Company and for whom such capital stock represents greater than 10% of such Person’s assets. 
 “Parent
Dividend” means any dividend or other distribution in respect of, or any redemption or repurchase of, the capital stock of any Parent, whether in cash, property or obligations of Parent, other than a dividend or other distribution payable
solely in the form of its capital stock. 
 “Parent Dividend Event” means the determination by any Parent to pay any Parent
Dividend with the proceeds of a Parent Recapitalization. 
 “Parent Recapitalization” means one or a series of related
recapitalization transactions (including the incurrence or issuance of Indebtedness, preferred stock or similar transactions) involving one or more Parents that beneficially own in the aggregate, directly or indirectly, a majority of the capital
stock of the Company. 
 “Permitted Junior Securities” means debt or equity securities of the Company or any successor
corporation issued pursuant to a plan of reorganization or readjustment of the Company that are subordinated to the payment of all then-outstanding Senior Debt at least to the same extent that this Note is subordinated to the payment of all Senior
Debt on the Closing Date, so long as to the extent that any holder of Designated Senior Debt outstanding on the date of consummation of any such plan of reorganization or readjustment is not paid in full in cash on such date, the holders of such
Designated Senior Debt not so paid in full in cash have consented to the terms of such plan of reorganization or readjustment. 

 “Person” means an individual, partnership, corporation, limited liability company,
association, trust, unincorporated organization, or a government or agency or political subdivision thereof. 
 “PIK Interest
Portion” is defined in Section 2 of this Note. 
 “Recapitalization Event” means any recapitalization transaction
(including the incurrence or issuance of Indebtedness, preferred stock or similar transactions) of the Company or any of its direct or indirect subsidiaries. 

“Receivables Financing” means any transaction or series of transactions that may be entered into by Affinia or any of its subsidiaries
pursuant to which Affinia or any of its subsidiaries may sell, convey or otherwise transfer to a Person formed for the purpose of engaging in such transaction or series of transactions, or may grant a security interest in, any accounts receivable
(whether now existing or arising in the future) of Affinia or any of its subsidiaries, and any assets related thereto including, without limitation, all collateral securing such accounts receivable, all contracts and all guarantees or other
obligations in respect of such accounts receivable, proceeds of such accounts receivable and other assets which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization
transactions involving accounts receivable. 
 “Securities Act” means the Securities Act of 1933, as amended, or any successor
Federal statute, and the rules and regulations promulgated thereunder. 
 “Seller Prepayment Portion” means (x) in
connection with any proposed Dividend by the Company that triggers a Dividend Event, an amount equal to 17.5% of the total amount of such proposed Dividend, (y) in connection with any proposed Dividend by a subsidiary of the Company that
triggers a Dividend Event, an amount equal to 17.5% of the total amount of such proposed Dividend that is paid to a Investor and (z) in connection with any proposed Parent Dividend that triggers a Parent Dividend Event, an amount equal to 17.5%
of the total amount of the Parent Dividend. 
 “Senior Debt” means all payment obligations (whether now outstanding or
hereafter incurred) of the Company and its subsidiaries in respect of (a) Indebtedness of the Company and its subsidiaries (including, without limitation, in respect of any Guaranty of any Indebtedness of any of its subsidiaries) other than
(1) this Note and (2) any Indebtedness that by its terms is expressly subordinated to this Note, (b) interest (including default interest) and premium on the outstanding Indebtedness referred to in clause (a) above, (c) the
fees and commissions (including commitment, agency and letter of credit fees and commissions) payable pursuant to the Senior Debt 

 Agreements, (d) all other payment obligations (including costs, expenses, penalties, indemnifications,
damages, liabilities or otherwise on the Company or any of its subsidiaries) owing under or arising pursuant to the Senior Debt Agreements not of the type described in clauses (a) through (c) above, and (e) post-petition interest on
the Indebtedness referred to in clauses (a) through (d) above accruing subsequent to the commencement of a proceeding under the Bankruptcy Code (whether or not such interest is allowed as a claim in such proceeding). Without limiting the
foregoing, Senior Debt shall include all Designated Senior Debt. 
 “Senior Debt Agreement” means each instrument or agreement
evidencing or governing the Indebtedness referred to in clause (a) of the definition of Senior Debt. 
 “Senior Debt
Default” means any default or event of default by the Company or any of its subsidiaries under any Senior Debt Agreement. 

“Senior Debt Representatives” means with respect to any Senior Debt Agreement, the lead agent or trustee for the lenders and/or
creditors thereunder. 
 “Senior Subordinated Note Indenture” means the Indenture entered into by Affinia as of
November 30, 2004 in connection with the issuance of its 9% Senior Subordinated Notes due 2014 and any Guaranties thereof by Intermediate Holdings or any of its subsidiaries, as amended, restated, supplemented, waived, replaced, restructured,
refinanced or otherwise modified from time to time. 
 “Subordinated Obligation” is defined in the first paragraph of
Section 7 of this Note. 
 “Voidable Transfer” is defined in Section 7.8 of this Note. 

SECTION 2. Interest. Interest shall accrue on a daily basis from the date hereof until this Note is paid in full on the unpaid
principal amount of this Note outstanding from time to time at the Interest Rate (computed on the basis of a 365- or 366-day year for the actual number of days elapsed) and shall be payable on each Interest Payment Date. Notwithstanding the
foregoing, at any time, at the option of the Company, interest on this Note may be paid in kind and not in cash or other property. On each Interest Payment Date, accrued interest that is then unpaid and that has not been previously added to the
principal amount of this Note shall be added to the principal amount of this Note and amounts so added (the “PIK Interest Portion”) shall thereafter be deemed to be a part of the principal amount of this Note from and after the date
so added. 

 SECTION 3. Payments. 

Section 3.1. Scheduled Payments. 

(a) Except in accordance with the provisions of Sections 3.2 and 3.3, this Note shall not be subject to any required
prepayment prior to the Maturity Date. 
 (b) On the Maturity Date, the Company shall pay the then outstanding
principal amount of this Note together with accrued interest thereon. 
 Section 3.2. Offer to Repay on Dividend Events
and Parent Dividend Events. Upon the occurrence of a Dividend Event or a Parent Dividend Event, the Company shall make an offer to prepay at the Actual Prepayment Value (or, in lieu of the Company making an offer, any Parent may make an offer),
the maximum portion of this Note and all other notes for which this Note has been exchanged pursuant to Section 10.1, including the related PIK Interest Portions thereof (which may be the entire outstanding principal amount), that may be
prepaid at the Actual Prepayment Value using the Seller Prepayment Portion. The Company will give Holder written notice of any Dividend Event or Parent Dividend Event not less than five Business Days prior to the date fixed for payment of a Dividend
in respect of such Dividend Event or a Parent Dividend in respect of a Parent Dividend Event, as applicable. Each such notice shall specify the date fixed for payment of the Dividend in respect of the Dividend Event or the Parent Dividend in respect
of a Parent Dividend Event, as applicable, the aggregate amount of the Dividend or Parent Dividend and the amount of the Seller Prepayment Portion applicable to this Note (which amount shall be based on a pro rata allocation of the Seller Prepayment
Portion among this Note and all other notes for which this Note has been exchanged pursuant to Section 10.1). In the event Holder elects to have a portion or all of this Note prepaid in the amount up to or equal to the Seller Prepayment Portion
applicable to this Note pursuant to this Section 3.2, Holder shall give the Company at least two Business Days notice prior to the date of such Dividend Event or Parent Dividend Event. The amount of the proposed Dividend or Parent Dividend
triggering the Company’s obligations under this Section 3.2 shall be reduced in an amount equal to the aggregate portion of the Seller Prepayment Portion actually used to prepay this Note and any other notes for which this Note has been
exchanged pursuant to Section 10.1 pursuant to this Section 3.2. In the event that Holder elects not to have a portion or all of this Note prepaid in the amount of the Seller Prepayment Portion applicable to this Note pursuant to this
Section 3.2, the Company or Parent shall have the right to pay the full proposed Dividend amount or Parent Dividend amount, as applicable, as contemplated in the notice described above (as reduced by any amounts used to prepay any other notes
for which this Note has been exchanged pursuant to Section 10.1). The amount of outstanding principal under this Note treated as 

 having been repaid upon payment of the Seller Prepayment Portion shall be calculated as set forth in the
definition of “Actual Prepayment Value.” Any prepayment shall be applied as set forth in Section 3.6. 

Section 3.3. Change of Control Put. 

(a) Upon a Change of Control, Holder shall have the right to require the Company to repurchase this Note at a purchase
price in cash equal to the Actual Prepayment Value without any premium or penalty (the “Change of Control Purchase Price”), in accordance with the terms contemplated in this Section 3.3. In the event that at the time of such
Change of Control the terms of the Indebtedness under any Senior Debt Agreement restrict or prohibit the repurchase of this Note (or a dividend or distribution by Affinia to the Company in an amount sufficient to make such repurchase), then prior to
the mailing of the notice to Holder provided for in paragraph (b) of this Section 3.3 but in any event within 60 days following any Change of Control, the Company shall, or shall cause Affinia to, (i) repay in full all Indebtedness
under all such Senior Debt Agreements or (ii) obtain the requisite consent under all such Senior Debt Agreements to permit the repurchase of this Note (or a dividend or distribution by Affinia to the Company in an amount sufficient to make such
repurchase), as provided for in paragraph (b) of this Section 3.3. 
 (b) Within 60 days following any
Change of Control, the Company shall mail a notice to Holder (the “Change of Control Offer”) stating: 

(i) that a Change of Control has occurred and that Holder has the right to require the Company to purchase this Note at
the Change of Control Purchase Price; 
 (ii) the circumstances and relevant facts regarding such Change of
Control; 
 (iii) the repurchase date (which shall be no earlier than 10 days nor later than 30 days from the
date such notice is mailed); and 
 (iv) the instructions, determined by the Company consistent with this
Section, that Holder must follow in order to have this Note purchased. 

 (c) If Holder elects to have this Note purchased it shall be required to
inform the Company and surrender this Note at the address specified in the notice at least three Business Days prior to the purchase date. Holder shall be entitled to withdraw its election if the Company receives not later than one Business Day
prior to the purchase date a telegram, telex, facsimile transmission or letter setting forth a statement that Holder is withdrawing its election to have this Note purchased. 

(d) On the purchase date, the Company shall pay the Change of Control Purchase Price to Holder. 

(e) Notwithstanding the foregoing provisions of this Section 3.3, the Company shall not be required to make a Change
of Control Offer upon a Change of Control if a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in paragraph (b) of this Section 3.3, applicable to a
Change of Control Offer made by the Company and purchases this Note validly tendered and not withdrawn under such Change of Control Offer. 

Section 3.4. Optional Prepayment. 

(a) Prior to an Optional Prepayment Event. Subject to Section 7 and prior to the occurrence of an Optional
Prepayment Event, the Company may, at its option, upon notice as provided below, prepay at any time all, or from time to time any part (in an integral multiple of U.S.$500,000 and a minimum of U.S.$1,000,000 or such lesser principal amount thereof
as shall then be outstanding) of this Note without any premium or penalty. The Company will give Holder written notice of each optional prepayment under this Section 3.4(a) not less than five Business Days prior to the date fixed for such
prepayment. Each such notice shall specify (i) the date fixed for prepayment, (ii) the aggregate principal amount of this Note to be prepaid on such date, and (iii) the interest to be paid on such date with respect to such principal
amount being prepaid. The amount payable in connection with any prepayment of this Note under this Section 3.4(a) shall be the then outstanding principal amount of the portion of this Note to be prepaid together with accrued interest thereon.
Any prepayment shall be applied as set forth in Section 3.6. 
 (b) After an Optional Prepayment
Event. Subject to Section 7 and after the occurrence of an Optional Prepayment Event, the Company may, at its option, upon notice as provided below, prepay at 

 
any time all, or from time to time any part (in an integral multiple of U.S.$500,000 and a minimum of U.S.$1,000,000 or such lesser principal amount thereof as shall then be outstanding) of this
Note without any premium or penalty; provided that the Company may not prepay an aggregate principal amount in excess of the aggregate proceeds to the Company of all transactions giving rise to the Optional Prepayment Event (less any proceeds used
to make a mandatory prepayment pursuant to either Section 3.2 or 3.3). The Company will give Holder written notice of each optional prepayment under this Section 3.4(b) not less than five Business Days prior to the date fixed for such
prepayment. Each such notice shall specify (i) the date fixed for prepayment, (ii) the aggregate principal amount of this Note to be prepaid on such date, and (iii) the interest to be paid on such date with respect to such principal
amount being prepaid. The amount payable in connection with any redemption prepayment of this Note under this Section 3.4(b) shall be the then applicable Actual Prepayment Value. Any prepayment shall be applied as set forth in Section 3.6.

 (c) Selection of Notes To Be Prepaid. If less than the aggregate principal amount of this Note and all
other notes for which this Note has been exchanged pursuant to Section 10.1 are to be repaid pursuant to Section 3.4, the Company shall select the Notes and such other notes to be redeemed on a pro rata basis. The Company shall make the
selection from outstanding Notes and other notes not previously prepaid. 
 Section 3.5. Payment Dates. Whenever any
payment of interest or principal under this Note is stated to be due on a day other than a Business Day, such payment shall be made on the next succeeding Business Day, and any such additional days elapsed shall be reflected in the computation of
the interest payable on such next succeeding Business Day. 
 Section 3.6. Maturity. Surrender, etc. Any prepayment
of this Note pursuant to this Section 3 shall become due and payable on the date fixed for such prepayment. From and after such date, unless the Company shall fail to make such prepayment when so due and payable, interest on such portion the
Note (including the PIK Interest Portion) to be prepaid at the Actual Prepayment Value shall cease to accrue. If, on any date, such prepayment is to be made at the Actual Prepayment Value, then if the prepayment of the Actual Prepayment Value with
respect to the total outstanding principal amount of the Note shall be paid in full, this Note shall be fully satisfied and cancelled, notwithstanding the fact that such Actual Repayment Amount on such date is less than the aggregate principal
amount of this Note (including the PIK Interest Portion) on such date. 

 SECTION 4. Covenants. The Company covenants that so long as this Note is outstanding:

 Section 4.1. Dividends. The Company will not (a) pay any Dividend from the proceeds of any Asset Sale Event
or Recapitalization Event without, in either case, making an offer to make the prepayments required by Section 3.2 or (b) permit any subsidiary of the Company to pay a Dividend to any Investor or its subsidiaries from the proceeds of any
Asset Sale Event or Recapitalization Event (provided that, for the purposes of this clause (b), neither the Company nor a subsidiary of the Company shall be considered a “subsidiary” of any Investor) without, in either case, making an
offer to make the prepayments required by Section 3.2. The Company shall not, and shall not permit its subsidiaries to, acquire any indebtedness of any Parent or make any loans or advances to any Parent in excess of $5 million in the aggregate
at any time outstanding from the proceeds of any Asset Sale Event or Recapitalization Event (except loans or advances to pay taxes of Parent that are attributable to the Company and its subsidiaries). 

Section 4.2. Affiliate Transactions. The Company will not, and will not permit any of its subsidiaries to, enter into any
contract, arrangement or other transaction with any Affiliate (other than the Company or any of its subsidiaries) without the unanimous approval of the Executive Committee of the Board of Directors of the Company or such subsidiary; provided,
however, that the payment of dividends or other distributions in respect of the capital stock of the Company or its subsidiaries shall not be subject to the requirements of this Section 4.2. For the avoidance of doubt, nothing in this
Section 4.2 shall be deemed to restrict any direct or indirect holder of the capital stock of the Company or any of their affiliates from entering into any contract, arrangement or other transaction with any subsidiary of the Company.

 Section 4.3. Financial Statements; Notice. The Company shall deliver to Holder (a) a copy of each financial
statement required to be delivered to the note holders pursuant to the terms of the Senior Subordinated Note Indenture, as and when so required (and, if the Senior Subordinated Note Indenture no longer requires delivery of any such financial
statements, the Company shall continue to deliver to Holder substantially similar financial statements) and (b) as promptly as practicable (but in any event not later than five Business Days) after the occurrence of any Default or Event of
Default, notice thereof in reasonable detail describing the nature and period of existence thereof. 

 SECTION 5. Events of Default. An “Event of Default”
shall exist if any of the following conditions or events shall occur and be continuing: 
 (a) the Company
defaults in the payment of any principal on this Note when the same becomes due and payable, whether at maturity or at a date fixed for prepayment; or 

(b) the Company defaults in the payment of any cash interest on this Note for more than 30 days after the same becomes due
and payable; or 
 (c) the Company defaults in the performance of or compliance with any of its agreements under
this Note (other than any other agreement described in this Section 5) and such failure continues for 60 days; or 

(d) the acceleration of any Designated Senior Debt by the holders thereof; or 

(e) the Company or Affinia (1) files, or consents by answer or otherwise to the filing against it of, a petition for
relief or reorganization or arrangement or any other petition in bankruptcy, seeking to adjudicate it as a bankrupt or insolvent, for liquidation or to take advantage of any bankruptcy, insolvency, reorganization, moratorium or other similar law of
any jurisdiction, (2) makes a general assignment for the benefit of its creditors, or (3) consents to the appointment of a custodian, receiver, trustee or other officer with similar powers with respect to it or with respect to any
substantial part of its property; or 
 (f) a court or Governmental Authority of competent jurisdiction enters an
order appointing, without consent by the Company or Affinia, a custodian, receiver, trustee or other officer with similar power s with respect to it or with respect to any substantial part of its property, or constituting an order for relief or
approving a petition for relief or reorganization or any other petition in bankruptcy or for liquidation or to take advantage of any bankruptcy or insolvency law of any jurisdiction, or ordering the dissolution, winding-up or liquidation of the
Company or Affinia, or petition for any action (including, without limitation, a petition in bankruptcy or seeking to adjudicate the Company or Affinia as a bankrupt of insolvent) shall be filed against the Company or Affinia and such petition shall
not be dismissed within 60 days. 

 SECTION 6. Remedies on Default. Etc. 

Section 6.1. Acceleration. 

(a) If an Event of Default with respect to the Company described in paragraph (e) or (f) of Section 5 has occurred, this
Note then shall automatically become immediately due and payable. 
 (b) If any Event of Default (other than as described in
paragraph (a) of this Section 6.1) has occurred and is continuing, Holder may, at any time at its option by notice to the Company declare this Note to be immediately due and payable. 

Upon this Note becoming due and payable under this Section 6.1, whether automatically or by declaration, this Note will forthwith mature and the
entire unpaid principal amount of this Note, plus all accrued and unpaid interest shall all be immediately due and payable, in each and every case without presentment, demand, protest or further notice, all of which are hereby waived. 

Section 6.2. Other Remedies. If any Default or Event of Default has occurred and is continuing, and irrespective of whether
this Note has become or has been declared immediately due and payable under Section 6.1, Holder may, subject to Section 7, proceed to protect and enforce its rights by an action at law, suit in equity or other appropriate proceeding,
whether for the specific performance of any agreement contained herein, or for an injunction against a violation of any of the terms hereof, or in aid of the exercise of any power granted hereby or by law or otherwise. 

Section 6.3. Rescission. At any time after this Note has been declared due and payable pursuant to paragraph (b) of
Section 6.1, Holder, by written notice to the Company, may (but in no event shall be obligated to) rescind and annul any such declaration and its consequences if (a) the Company has paid all overdue interest on this Note and all principal
of this Note that is due and payable and is unpaid other than by reason of such declaration, (b) all Defaults and Events of Default, other than non-payment of amounts that have become due solely by reason of such declaration, have been cured or
have been waived pursuant to Section 8, and (c) no judgment or decree has been entered for the payment of any monies due pursuant hereto. No rescission and annulment under this Section 6.3 will extend to or affect any subsequent
Default or Event of Default or impair any right consequent thereon. 
 Section 6.4. No Waivers or Election of Remedies,
Expenses, Etc. No right, power or remedy conferred by this Note upon Holder shall be exclusive of any other right, power or remedy referred to herein or now or hereafter available at law, in equity, by statute or otherwise. The Company will pay
to Holder on demand such further amount as shall be sufficient to cover all reasonable costs and expenses of Holder incurred in any enforcement or collection under this Section 6, including, without limitation, reasonable attorneys’ fees,
expenses and disbursements. 

 SECTION 7. Subordination. Anything in this Note to the contrary notwithstanding,
Holder and each subsequent holder of this Note by its acceptance hereof covenants and agrees that the payment of the principal of and interest on this Note and all other amounts payable by the Company under or in respect of this Note (all of the
foregoing, the “Subordinated Obligations”) shall, to the extent set forth in this Section 7, be subordinate and junior and subject in right of payment to the prior payment in full in cash of all Senior Debt. 

Section 7.1. Payments. No payment or distribution (whether directly, by purchase or redemption by right of set-off or
otherwise in respect of this Note, whether as principal, interest or otherwise, and whether in cash, securities or property) shall be made by or on behalf of the Company or received and retained, directly or indirectly, by or on behalf of Holder
unless and until all Senior Debt has been paid in full in cash to the holders of the Senior Debt. Notwithstanding the immediately preceding sentence, the Company may (a) make payments of interest in kind under this Note when due and payable
pursuant to Section 2, (b) make any such payment or distribution so long as no Senior Debt Default exists on the date of such payment or would result from the making of such payment and (c) make any such payment or distribution
without r egard to the foregoing if the Company receives the written consent of the requisite holders of the Designated Senior Debt (or any duly authorized Senior Debt Representative). 

Section 7.2. Insolvency; Bankruptcy; Etc. 

(a) In the event of the institution of any Insolvency Proceeding relative to the Company, then 

(i) the holders of Senior Debt shall be entitled to receive payment in full in cash of all Senior Debt before Holder is
entitled to receive any payment in respect of the Subordinated Obligations; and 
 (ii) any payment or
distribution of any kind or character, whether in cash, property or securities, by setoff or otherwise, which may be payable or deliverable in such proceedings in respect of the Subordinated Obligations shall (notwithstanding any other provision of
this Note, including Section 7.1) be paid or delivered by the Person making such payment or distribution, whether a trustee in bankruptcy, a 

 
receiver, a liquidating trustee, or otherwise, directly to the holders of the Senior Debt to the extent necessary to make payment in full in cash of all Senior Debt remaining unpaid. 

(b) If Holder does not file a proper claim or proof of claim or other document or amendment thereof in the form required
in any Insolvency Proceeding relative to the Company under applicable law prior to 15 days before the expiration of time to file such claim or other document or amendment thereof, then the holders of the Designated Senior Debt shall have the right
(but not the obligation) in such Insolvency Proceeding, and hereby irrevocably are appointed lawful attorney of Holder for the purpose of enabling the holders of such Senior Debt, to file and prove all claims therefor and to execute and deliver all
documents in such proceeding in the name of Holder or in the name of the holders of such Senior Debt or otherwise in respect of such claims, as the holders of such Senior Debt reasonably may determine to be necessary or appropriate to effectuate the
foregoing, provided, that the holders of such Senior Debt shall act in a commercially reasonable manner and shall notify Holder prior to commencing the first of any such actions. 

Section 7.3. Standstill. Until the Senior Debt is paid in full in cash, Holder shall (notwithstanding the provisions of
Section 6) be prohibited from accelerating this Note and shall be prohibited from enforcing any of its default remedies with respect thereto (including any right to sue the Company or to file or participate in the filing of an involuntary
bankruptcy petition against the Company), except that this Section 7.3 shall (a) not prevent automatic acceleration of this Note under Section 6.1(a) or prohibit the filing of a proper claim or proof of debt or other document or
amendment thereof required in any Insolvency Proceeding or (b) not prevent Holder from accelerating this Note pursuant to Section 6.1(b) upon the first to occur of (a) the 270th day after (i) the due date of the prepayment
required pursuant to Section 3.2, if any, or the Maturity Date, as applicable, has occurred, (ii) the date on which the Senior Debt Representative with respect to any Designated Senior Debt or any holder of Designated Senior Debt commences
a judicial proceeding to collect any Designated Senior Debt or commences to realize upon any collateral for any such Designated Senior Debt pursuant to the exercise of remedies or gives notice of any non-judicial sale of any such collateral or
(iii) the occurrence of an Event of Default, unless such Event of Default has been cured or waived in accordance herewith, and, in any case, Holder has delivered notice thereof to each Senior Debt Representative in respect of any outstanding
Designated Senior Debt, or (b) the date on which any payment of any Designated Senior Debt is accelerated. 

 Section 7.4. No Impairment. (a) No right of any present or future holder of
Senior Debt to enforce subordination as herein provided shall at any time in any way be prejudiced or impaired by any act or failure to act on the part of the Company or by any non-compliance by the Company with the terms, provisions and covenants
of this Note, regardless of any knowledge thereof Holder may have or be otherwise charged with. 
 (b) Without in any way
limiting the generality of the foregoing paragraph, the holders of the Senior Debt may, at any time and from time to time, without the consent of or notice to Holder, without incurring responsibility and without impairing or releasing the
subordination provided in this Section 7, do any one or more of the following: (1) change the manner, place or terms of payment or extend the time of payment of, or renew, amend, modify, or alter, any Senior Debt or any Senior Debt
Agreement evidencing the same or evidencing, governing, creating, guaranteeing or securing any Senior Debt; ‘ (2) sell, exchange, release, or otherwise deal with any property pledged, mortgaged or otherwise securing Senior Debt;
(3) release any Person liable in any manner for the collection of Senior Debt; (4) fail or delay in the perfection of liens securing the Senior Debt, (5) exercise or refrain from exercising any rights against the Company and any other
Person (including, without limitation, actions with respect to the foreclosure upon, sale, release or failure to realize upon, any of its collateral, and actions with respect to the collection of any claim for all or any part of the Senior Debt from
any account debtor or any other Person, regardless of whether any such actions or omissions may affect the rights of the holders of the Senior Debt to a deficiency) and (6) from time to time enter into agreements and settlements with the
Company as it may determine, including, without limitation, any substitution of collateral, any release of any lien and any release of the Company. 

Section 7.5. Relative Rights. The provisions of this Section 7 are for the purpose of defining the relative rights of
the holders of Senior Debt on the one hand, and Holder on the other hand, and nothing herein shall impair, as between the Company and Holder, the obligation of the Company, which is unconditional and absolute, to pay to Holder the principal hereof
and interest hereon in accordance with the terms and provisions of this Note, subject to the rights, if any, of holders of Senior Debt under this Section 7. The fact that failure to make any payment on account of the Subordinated Obligations is
caused by reason of the operation of any provision of this Section 7 shall not be construed as preventing the occurrence of an Event of Default. 

Section 7.6. Subrogation. Upon payment in full in cash of all Senior Debt, Holder shall, to the extent of any payments or
distributions paid or delivered to the holders of the Senior Debt or otherwise applied to the Senior Debt pursuant to the provisions of this Section 7, be subrogated to the rights 

 of the holders of the Senior Debt to receive payments or distributions of assets of the Company made on
Senior Debt (and any security therefor) until the Subordinated Obligations shall be paid in full in cash, and, for the purposes of such subrogation, no payments to the holders of Senior Debt of any cash, assets, stock, or obligations to which Holder
would be entitled except for the provisions of this Section 7 shall, as between the Company, its creditors (other than the holders of the Senior Debt), and Holder, be deemed to be a payment by the Company to or on account of Senior Debt.

 Section 7.7. Turnover of Payments. If, notwithstanding the provisions of this Section 7, any payment or
distribution of any character (whether in cash, securities or other property) or any security shall be received by Holder in contravention of this Section 7 and before all Senior Debt shall have been paid in full in cash, after giving effect
to, and application of, all payments and distributions received by holders of Senior Debt from any other source, such payment, distribution or security shall be held in trust for the benefit of, and shall be immediately paid over or delivered or
transferred to, the holders of Senior Debt (or any duly authorized Senior Debt Representative) for application of payment according to the priorities of such Senior Debt and ratably among the holders of any class of Senior Debt (except that Holder
may receive and retain Permitted Junior Securities). 
 Section 7.8. Recoveries: Reinstatement. If a claim is made
upon any holder or holders of Senior Debt for repayment or recovery of any amount (a “Voidable Transfer”) on account of any Senior Debt under any Federal, state or foreign law, whether by reason of preference, fraudulent conveyance,
or otherwise and if such holder or holders of Senior Debt repay all or a portion of such amounts by reason of (a) any judgment, decree, or order of any court or administrative body having jurisdiction over such holder or holders, or
(b) any settlement or compromise of any claim effected by such holder or holders based upon the reasonable advice of counsel, then, as to the amount that has been repaid, the provisions of this Section 7 automatically shall be reinstated
and restored and the amount so repaid shall constitute Senior Debt entitled to the benefits of this Section 7 as if such Voidable Transfer never had been made. 

Section 7.9. Reliance by Holders of Senior Debt. The provisions of this Section 7 shall constitute a continuing offer to
all Persons who become holders of Senior Debt, and such provisions are made for the benefit of, and may be enforced directly by, holders of Senior Debt, who hereby are expressly stated to be intended beneficiaries of this Section 7, whether or
not they actually relied thereon. Holder covenants that it will not enter into any amendment or modification of the provisions of this Section 7 (and the related definitions) without having obtained the prior written consent of the 

 holders of the Designated Senior Debt. No right of a holder of Senior Debt to enforce the provisions of this
Section 7 shall be impaired by any act or failure to act by Holder or by the failure of the Holder to comply with the terms of this Note. 

Section 7.10. Payments to Senior Debt Representative. Any payment or distribution to be paid or delivered to the holders of
the Senior Debt under the provisions of this Section 7 may be paid or delivered to one or more Senior Debt Representatives for such holders. Holder- shall be entitled to rely on the delivery to it of a written notice purported to be signed on
behalf of an officer or representative of any Senior Debt Representatives believed by it in good faith to be genuine to establish the identity of such Senior Debt Representatives, the amount of the outstanding Senior Debt and other matters relevant
to the provisions of this Section 7. 
 SECTION 8. Amendment and Waiver. 

Section 8.1. Requirements. Subject to Section 7.9, this Note may be amended, and the observance of any term hereof may
be waived (either retroactively or prospectively), with (and only with) the written consent of the Company and Holder. 

Section 8.2. Binding Effect, Etc. Any amendment or waiver consented to as provided in this Section 8 is binding upon
Holder, each subsequent holder of this Note and upon the Company without regard to whether this Note has been marked to indicate such amendment or waiver. No such amendment or waiver will extend to or affect any obligation, covenant, agreement,
Default or Event of Default not expressly amended or waived or impair any right consequent thereon. 
 No course of dealing between the Company
and Holder nor any delay in exercising any rights hereunder shall operate as a waiver of any rights of Holder. As used herein, the term “this Note” and references hereto shall mean this Note as it may from time to time be amended or
supplemented. 
 SECTION 9. Notices. All notices and communications provided for hereunder shall be in writing and sent
(a) by facsimile if the sender on the same day sends a confirming copy of such notice by a recognized overnight delivery service (charges prepaid), or (b) by registered or certified mail with return receipt requested (postage
prepaid) or (c) by a recognized overnight delivery service (with charges prepaid). Any such notice must be sent to the address specified on Exhibit 1 attached hereto, or at such other address as the Company or the Holder, as the case may be,
shall have specified to the Holder or Company, as applicable, in writing. Notices under this Section 9 will be deemed given only when actually received. 

 SECTION 10. Miscellaneous. 

Section 10.1. Transfer or Exchange. This Note may be transferred or exchanged in whole or in part (in an integral multiple of
U.S.$10,000,000 and a minimum of U.S.$10,000,000 or such lesser principal amount thereof as shall then be outstanding) in compliance with any applicable securities laws with the prior written consent of the Company (such consent not to be
unreasonably withheld if such transfer or exchange would not adversely affect the Company and its Affiliates). Whenever the Note shall be surrendered for transfer or exchange, the Company at its expense will execute and deliver in exchange therefor
a new Note or Notes (in such denominations as may be requested by the holder of the surrendered Note), in the same aggregate unpaid principal amount and same aggregate stated principal amount as that of the Note so surrendered. The Company will
take, or will cause to be taken, such action as any holder of the Note may reasonably request from time to time to facilitate any sale or disposition by any such holder of the Note without registration under the Securities Act, and/or any applicable
securities laws within the limitation of the exemptions provided by any rule or regulation thereunder, including, without limitation, Rule 144A under the Securities Act. Any attempted transfer or exchange of all or a portion of the Note in violation
of this Section 10.1 shall be null and void. 
 Section 10.2. Successors and Assigns. All covenants and other
agreements contained in this Note by or on behalf of any of the parties hereto bind and inure to the benefit of their respective successors and assigns (including, without limitation, any subsequent permitted holder of this Note) whether so
expressed or not. 
 Section 10.3. Severability. Any provision of this Note that is prohibited or unenforceable in
any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall (to
the full extent permitted by law) not invalidate or render unenforceable such provision in any other jurisdiction. 

Section 10.4. Construction. Each covenant contained in this Note shall be construed (absent express provision to the
contrary) as being independent of each other covenant contained herein, so that compliance with any one covenant shall not (absent such an express contrary provision) be deemed to excuse compliance with any other covenant. Where any provision in
this Note refers to action to be taken by any Person, or which such Person is prohibited from taking, such provision shall be applicable whether such action is taken directly or indirectly by such Person. 

 Section 10.5. Integration. This Note embodies the entire agreement and
understanding between the Company and Holder and supersedes all prior agreements and understandings relating to the subject matter hereof. 

 Section 10.6. GOVERNING LAW. THIS NOTE AND THE RIGHTS AND OBLIGATIONS OF THE
PARTIES SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 
  

					
	AFFINIA GROUP HOLDINGS INC.	 	
			
	By:	 	/s/     Thomas Madden        	 	
		 	Name: Thomas Madden

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]